However, on October 7, 2024, the Outsourcing Facilities Association ( OFA ) filed suit against FDA in federal court in Fort Worth, alleging that FDAs decision to remove tirzepatide from the shortage list violated the Administrative Procedure Act (APA) because, inter alia , FDA failed to provide notice and seek comments from affected stakeholders
Treatment Pathway: Name-Brand First, Compounding When Appropriate When GLP-1 medications are prescribed, the preferred first option is always an FDA-approved, name-brand medication such as Wegovy or Zepbound, dispensed through a standard retail or manufacturer-direct pharmacy
These effects were achieved under reduced activation of noncanonical signaling pathways including receptor internalization and -arrestin recruitment, an initially surprising observation as these have previously been linked to increased GLP-1R responses when measured acutely 10,14,36
Are Natural Options Available Instead of GLP-1 During Pregnancy